Results 281 to 290 of about 125,713 (396)

Thiostrepton Suppresses the Progression of Rhabdomyosarcoma by Inhibiting the PI3K‐AKT Signaling Pathway

Pediatric Discovery, EarlyView.
The study establish TST as a multi‐mechanism PI3K‐AKT inhibitor for refractory RMS while validating Cmap‐driven drug repurposing for pediatric oncology. ABSTRACT Rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma with 5‐year survival below 30% in high‐risk/metastatic cases, was investigated through integrated bioinformatics analysis (
Yu Wang, Peng Hong, Zhiqiang Gao, Wei Ma, Zaihong Hu, Jie Lin, Kongkong Cui, Qinlin Shi, Xiao‐Mao Tian, Guanghui Wei   +9 more
wiley   +1 more source

Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.

European Journal of Cancer, 2017
L. Campiotti, M. Suter, L. Guasti, R. Piazza, C. Gambacorti-Passerini, A. Grandi, A. Squizzato   +6 more
semanticscholar   +1 more source

Insights into existing and futuristic treatment approach for chronic myeloid leukaemia. [PDF]

Indian J Med Res
Tyagi S, Singh A, Sharma N, Chaturvedi R, Kushwaha HR.   +4 more
europepmc   +1 more source

Proteomic Analysis of Bone Marrow CD138+ Cells to Identify Proteins Associated With the Response of Multiple Myeloma Patients to Commonly Used Therapeutic Regimens

PROTEOMICS, EarlyView.
ABSTRACT Multiple myeloma (MM) remains incurable; gaps in our understanding of MM molecular pathogenesis and drugs’ resistance mechanisms are involved in the failure of therapies. This study aims to identify proteins significantly impacting MM patients’ response to commonly used therapeutic regimens.
Foteini Paradeisi, Aggeliki Tserga, Vasiliki Lygirou, Manousos Makridakis, Rafael Stroggilos, Grigoris Georgiou, George M. Spyrou, Ioannis V. Kostopoulos, Christine‐Ivy Liacos, Aikaterini Termentzi, Meletios A. Dimopoulos, Ourania Tsitsilonis, Antonia Vlahou, Efstathios Kastritis, Jerome Zoidakis   +14 more
wiley   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase

, 2004
Patrick Hayden, Fiona Keogh, Mairead Ni Conghaile, Michael Carroll, Maeve P. Crowley, Nicola Fitz-Simon, N. Gardiner, Elisabeth Vandenberghe, J O’Riordan, Shaun R. McCann   +9 more
openalex   +1 more source

Phenotypically plastic drug-resistant chronic myeloid leukaemia cell line displays enhanced cellular dynamics in a zebrafish xenograft model. [PDF]

J Cell Mol Med
Baykal S, Yuce Z, Ozhan G.
europepmc   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Late presentation of chronic myeloid leukaemia patients in a low-income country: the prognostic implications and impact on treatment outcome. [PDF]

BMC Res Notes
Nelson EA, Ahmed IO, Bolarinwa RA, Adeagbo BA, Adegbola AJ, Salawu L, Bolaji OO, Durosinmi MA.   +7 more
europepmc   +1 more source